SaniSure, a global developer and manufacturer of single-use technology for the biopharmaceutical industry, has acquired New Jersey-based GL Engineering (GLE).
With this acquisition, SaniSure will expand its global integrated offering of drug product fill and finish bioprocessing assemblies and solutions including:
- Adding new capabilities and manufacturing capacities for drug product filling needles and assemblies
- GLE will become the centre of excellence for the development of drug product filling solutions
- Extension of the SaniSure sterile manufacturing platform with a strong focus on final filling
The acquisition complements each company's technical capabilities, product offering and commercial reach. SaniSure has a direct sales force in the US and Europe together with strategic regional distributors and manufacturer representatives. GLE is a leader in filling needle design and manufacturing.
"We are very excited about the addition of GLE to our innovative product portfolio," said SaniSure's CEO Thomas Hook. "GLE's high-quality, global standards filling needle line represents an important expansion to SaniSure's customer-focused solutions. Drug product filling solutions are a critical step in many of our customers' processes. Having the ability to vertically integrate GLE's solutions is quite unique."
Global demand for single-use technology is increasing rapidly with increasing R&D activities, a high level of biotech investments and strong global markets fueling a double-digit market growth rate.
"SaniSure's assembly capabilities and commercial reach will significantly enhance the commercialisation of our unique single-use needle design," said GL Engineering Founder, Gerhard Liepold.
Liepold, who will now join SaniSure as the Global Product Manager for Drug Product Filling Solutions, added: "We are very proud to join the SaniSure team and bring more than two decades of pharmaceutical industry experience with strong engineering and commitment to design innovation in the single-use market."
